Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-73763989 plus nucleos(t)ide analogs and PD-1 inhibitor in chronic hepatitis B
ISRCTN15803686Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised trial of tomligisiran, tenofovir disoproxil fumarate, tenofovir alafenamide and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants who achieve hepatitis B surface antigen seroclearance. Started May 2022; status: completed.
02
Drugs
tomligisirantenofovir disoproxil fumaratetenofovir alafenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ISRCTN15803686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15803686.